Head and neck squamous cancer cells enhance the differentiation of human mesenchymal stem cells to adipogenic and osteogenic linages
adipogenic differentiation
head and neck squamous cell carcinoma
human mesenchymal stem cell
osteogenic differentiation
tumor microenvironment
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
28
08
2021
accepted:
09
08
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
Human mesenchymal stem cells (hMSC) are multipotent cells with the ability to differentiate into a range of different cell types, including fat, bone, cartilage or muscle. A pro-tumorigenic effect of hMSC has been previously reported as part of the tumor stroma. In addition, studies have previously revealed the influence of hematopoietic and lymphoid tumors on hMSC differentiation to support their own growth. However, this possible phenomenon has not been explored in solid malignancies. Therefore, the aim of the present study was to investigate the effects of head and neck squamous cell carcinoma (HNSCC) lines Cal27 and HLaC78 on the induction of osteogenic and adipogenic differentiation in hMSCs. Native hMSCs were co-cultured with Cal27 and HLaC78 cells for 3 weeks. Subsequently, hMSC differentiation was assessed using reverse transcription-PCR and using Oil Red O and von Kossa staining. Furthermore, the effects of differentiated hMSCs on Cal27 and HLaC78 were examined. For this purpose, hMSCs differentiated into the adipogenic (adipo-hMSC) and osteogenic (osteo-hMSC) lineages were co-cultured with Cal27 and HLaC78. Cell viability, cytokine secretion and activation of STAT3 signaling were measured by cell counting, dot blot assay (42 cytokines with focus on IL-6) and western blotting (STAT3, phosphorylated STAT3, β-actin), respectively. Co-culturing hMSCs with Cal27 and HLaC78 cells resulted in both adipogenic and osteogenic differentiation. In addition, the viability of Cal27 and HLaC78 cells was found to be increased after co-cultivation with adipo-hMSCs, compared with that of cells co-cultured with osteo-hMSC. According to western blotting results, Cal27 cells incubated with adipo-hMSCs exhibited increased STAT3 activation, compared with that in cells co-cultured with native hMSCs and osteo-hMSCs. IL-6 concentration in the media of Cal27 and HLaC78 after co-cultivation with respectively incubation with conditioned media of hMSCs, adipo-hMSCs and osteo-hMSCs were also found to be increased compared with that in the media of Cal27 and HLaC78 cells incubated with DMEM. To conclude, HNSCC cell lines Cal27 and HLaC78 induced hMSC differentiation towards the adipogenic and osteogenic lineages
Identifiants
pubmed: 36420071
doi: 10.3892/ol.2022.13570
pii: OL-24-06-13570
pmc: PMC9647781
doi:
Types de publication
Journal Article
Langues
eng
Pagination
450Informations de copyright
Copyright: © Meyer et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Oncol Lett. 2019 Jan;17(1):747-756
pubmed: 30655826
Cancer Metastasis Rev. 2010 Jun;29(2):249-61
pubmed: 20411303
Cell Physiol Biochem. 2004;14(4-6):311-24
pubmed: 15319535
Liver Transpl. 2012 Jun;18(6):696-706
pubmed: 22344929
World J Biol Chem. 2015 May 26;6(2):39-47
pubmed: 26009703
Cancer Metastasis Rev. 2016 Sep;35(3):413-26
pubmed: 27194534
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Arch Med Res. 2003 Nov-Dec;34(6):565-71
pubmed: 14734097
Regen Med. 2019 Mar;14(3):213-230
pubmed: 30762487
Vaccines (Basel). 2016 Nov 08;4(4):
pubmed: 27834810
Int J Cancer. 2016 Jun 1;138(11):2570-8
pubmed: 26559373
Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11917-23
pubmed: 13679583
Cytotherapy. 2005;7(5):393-5
pubmed: 16236628
Eur J Cancer Clin Oncol. 1988 Sep;24(9):1445-55
pubmed: 3181269
J Cell Biochem. 2006 Jun 1;98(3):538-54
pubmed: 16317727
Cancer Res. 2008 Jun 1;68(11):4331-9
pubmed: 18519693
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Int J Cancer. 2009 Nov 1;125(9):2159-65
pubmed: 19569190
Exp Cell Res. 2014 Jan 1;320(1):164-73
pubmed: 24183998
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679949
Front Cell Dev Biol. 2014 Sep 12;2:50
pubmed: 25364757
Curr Treat Options Oncol. 2016 Jul;17(7):37
pubmed: 27262711
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
PLoS One. 2009;4(4):e4992
pubmed: 19352430
Cancer Biol Ther. 2011 Feb 1;11(3):349-57
pubmed: 21127403
Front Oncol. 2021 Feb 18;10:584683
pubmed: 33680918
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Arch Otorhinolaryngol. 1979;225(4):269-77
pubmed: 548013
PLoS One. 2011;6(6):e20526
pubmed: 21694780
Cancer Res. 2015 Nov 15;75(22):4753-65
pubmed: 26404004
Cell Death Dis. 2017 Jan 19;8(1):e2568
pubmed: 28102844
Biochem J. 2003 Aug 15;374(Pt 1):1-20
pubmed: 12773095
Bone Res. 2019 Nov 14;7:35
pubmed: 31754546
Endocrinology. 2007 Jun;148(6):2635-43
pubmed: 17395698
Mol Cell Endocrinol. 2010 Mar 25;316(2):129-39
pubmed: 19723556
Cell Adh Migr. 2012 May-Jun;6(3):220-30
pubmed: 22863739
Stem Cell Rev Rep. 2011 Sep;7(3):560-8
pubmed: 21437576
Laryngorhinootologie. 2018 Oct;97(10):678-687
pubmed: 30340228
Leukemia. 2007 May;21(5):1079-88
pubmed: 17344918